Page 77 - The Flying Publisher Guide to Hepatitis C Treatment

Searching for new antiviral therapies | 77

characteristics, as well as reviewed on-treatment predictors and
detection of resistant mutations. The importance of genetic
markers such as the IL28B polymorphism on the SVR during
triple therapy is not yet known.
According to the available data, the combinations of DAAs will
still require a backbone of PegIFN/RBV in order to attain
complete viral suppression and to avoid virologic breakthrough
and resistance. However, this will be affected by costs, increased
toxicities and emergence of viral resistance. For this reason, a lot
of effort is directed to the parallel development of multidrug
regimens that may offer independence from PegIFN/RBV,
providing new hope for patients who are intolerant or have
contraindications to to PegIFN/RBV. Future treatment strategies
will include combinations of several DAAs with different
mechanisms of action, together with host modulators and drugs
addressing innate immunity against HCV.

Links
– European Agency for Medicines: www.ema.europa.eu
– U.S. Food and Drug Administration (FDA):
www.fda.gov/Drugs
– EASL: 5th Clinical Practice Guidelines on the Management of
Hepatitis C Virus Infection:
www.easl.eu/_clinical-practice-guideline
– Treatment for chronic hepatitis C and co-infection with
HIV/HCV: www.hivandhepatitis.com
– Hepatitis C Medication: http://pharmexec.findpharma.com

– Abbott: www.abbott.com
– Achillion Pharmaceuticals: www.achillion.com
– Anadys Pharmaceuticals: www.anadyspharma.com
– AstraZeneca : www.astrazeneca.com
– BMS: www.bms.com
– Boehringer Ingelheim: www.boehringer-ingelheim.com
– Gilead: www.gilead.com
– IDX: www.idenix.com